|
1
|
Spira AI and Ettinger DS: The use of
chemotherapy in soft-tissue sarcomas. Oncologist. 7:348–359. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matushansky I, Charytonowicz E, Mills J,
Siddiqi S, Hricik T and Cordon-Cardo C: MFH classification:
differentiating undifferentiated pleomorphic sarcoma in the 21st
Century. Expert Rev Anticancer Ther. 9:1135–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Papai Z, Bodoky G, Szanto J, et al: The
efficacy of a combination of etoposide, ifosfamide and cisplatin in
the treatment of patients with soft tissue sarcoma. Cancer.
89:177–180. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jain A, Sajeevan K, Babu K and Lakshmaiah
K: Chemotherapy in adult soft tissue sarcoma. Indian J Cancer.
46:274–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pitti RM, Marsters SA, Lawrence DA, et al:
Genomic amplification of a decoy receptor for Fas ligand in lung
and colon cancer. Nature. 396:699–703. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and
Kwon BS: A newly identified member of tumor necrosis factor
receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J
Biol Chem. 274:13733–13736. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Migone TS, Zhang J, Luo X, et al: TL1A is
a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
9
|
Strasser A, Jost PJ and Nagata S: The many
roles of FAS receptor signaling in the immune system. Immunity.
30:180–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ho CH, Chen CL, Li WY and Chen CJ: Decoy
receptor 3, upregulated by Epstein-Barr virus latent membrane
protein 1, enhances nasopharyngeal carcinoma cell migration and
invasion. Carcinogenesis. 30:1443–1451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ge Z, Sanders AJ, Ye L, Wang Y and Jiang
WG: Expression of death decoy receptor-3 (DcR3) in human breast
cancer and its functional effects on breast cancer cells in vitro.
J Exp Ther Oncol. 9:109–118. 2011.PubMed/NCBI
|
|
12
|
Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL
and Lin WW: Soluble decoy receptor 3 induces angiogenesis by
neutralization of TL1A, a cytokine belonging to tumor necrosis
factor superfamily and exhibiting angiostatic action. Cancer Res.
64:1122–1129. 2004. View Article : Google Scholar
|
|
13
|
Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu
TL and Lin WW: Decoy receptor 3 (DcR3) induces osteoclast formation
from monocyte/macrophage lineage precursor cells. Cell Death
Differ. 11(Suppl 1): S97–S107. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu SF, Liu TM, Lin YC, et al:
Immunomodulatory effect of decoy receptor 3 on the differentiation
and function of bone marrow-derived dendritic cells in nonobese
diabetic mice: from regulatory mechanism to clinical implication. J
Leukoc Biol. 75:293–306. 2004.
|
|
15
|
Hayashi S, Nishiyama T, Miura Y, et al:
DcR3 induces cell proliferation through MAPK signaling in
chondrocytes of osteoarthritis. Osteoarthritis Cartilage.
19:903–910. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
You RI, Chang YC, Chen PM, et al:
Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3).
Blood. 111:1480–1488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hsu MJ, Lin WW, Tsao WC, et al: Enhanced
adhesion of monocytes via reverse signaling triggered by decoy
receptor 3. Exp Cell Res. 292:241–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ohshima K, Haraoka S, Sugihara M, et al:
Amplification and expression of a decoy receptor for fas ligand
(DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett.
160:89–97. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roth W, Isenmann S, Nakamura M, et al:
Soluble decoy receptor 3 is expressed by malignant gliomas and
suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer
Res. 61:2759–2765. 2001.PubMed/NCBI
|
|
20
|
Tsuji S, Hosotani R, Yonehara S, et al:
Endogenous decoy receptor 3 blocks the growth inhibition signals
mediated by Fas ligand in human pancreatic adenocarcinoma. Int J
Cancer. 106:17–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Imabori M, Akisue T, Kishimoto K, et al:
Expression of DcR3 in bone and soft tissue tumors. Cancer Ther.
7:43–48. 2009.
|
|
22
|
Macher-Goeppinger S, Aulmann S, Wagener N,
et al: Decoy receptor 3 is a prognostic factor in renal cell
cancer. Neoplasia. 10:1049–1056. 2008.PubMed/NCBI
|
|
23
|
Chen G and Luo D: Over-expression of decoy
receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med
Sci. 113:297–304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen G and Luo D: Expression of decoy
receptor 3 in liver tissue microarrays. Natl Med J India.
21:275–278. 2008.PubMed/NCBI
|
|
25
|
Chang PM, Chen PM, Hsieh SL, et al:
Expression of a soluble decoy receptor 3 in patients with diffuse
large B-cell lymphoma predicts clinical outcome. Int J Oncol.
33:549–554. 2008.PubMed/NCBI
|
|
26
|
Fujita Y, Sakakura C, Shimomura K, et al:
Chromosome arm 20q gains and other genomic alterations in
esophageal squamous cell carcinoma, as analyzed by comparative
genomic hybridization and fluorescence in situ hybridization.
Hepatogastroenterology. 50:1857–1863. 2003.
|
|
27
|
Takahama Y, Yamada Y, Emoto K, et al: The
prognostic significance of overexpression of the decoy receptor for
Fas ligand (DcR3) in patients with gastric carcinomas. Gastric
Cancer. 5:61–68. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choong PFM: The molecular basis of
skeletal metastases. Clin Orthop Relat Res. 415:S192003. View Article : Google Scholar
|
|
29
|
Hidalgo M and Eckhardt SG: Development of
matrix metalloproteinase inhibitors in cancer therapy. J Natl
Cancer Inst. 93:178–193. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:163–176. 2002. View
Article : Google Scholar
|
|
31
|
Ohnishi Y, Ito Y, Tajima S, Ishibashi A
and Arai K: Immunohistochemical study of membrane type-matrix
metalloproteinases (MT-MMPs) and matrix metalloproteinase-2 (MMP-2)
in dermatofibroma and malignant fibrous histiocytoma. J Dermatol
Sci. 28:119–125. 2002. View Article : Google Scholar
|
|
32
|
Ahlen J, Enberg U, Larsson C, et al:
Malignant fibrous histiocytoma, aggressive fibromatosis and benign
fibrous tumors express mRNA for the metalloproteinase inducer
EMMPRIN and the metalloproteinases MMP-2 and MT1-MMP. Sarcoma.
5:143–149. 2001. View Article : Google Scholar
|
|
33
|
Nakatani T, Marui T, Yamamoto T, Kurosaka
M, Akisue T and Matsumoto K: Establishment and characterization of
cell line TNMY1 derived from human malignant fibrous histiocytoma.
Pathol Int. 51:595–602. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kiyozuka Y, Nakagawa H, Uemura Y, et al:
Novel cell lines established from a human myxoid malignant fibrous
histiocytoma arising in the uterus. Cancer Genet Cytogenet.
127:7–15. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: a convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Albini A: Tumor and endothelial cell
invasion of basement membranes. The matrigel chemoinvasion assay as
a tool for dissecting molecular mechanisms. Pathol Oncol Res.
4:230–241. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Troeberg L and Nagase H: Zymography of
metalloproteinases. Curr Protoc Protein Sci. Chapter 21(Unit 21):
152004.PubMed/NCBI
|
|
38
|
Yang CR, Guh JH, Teng CM, Chen CC and Chen
PH: Combined treatment with denbinobin and Fas ligand has a
synergistic cytotoxic effect in human pancreatic adenocarcinoma
BxPC-3 cells. Br J Pharmacol. 157:1175–1185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reuben PM and Cheung HS: Regulation of
matrix metalloproteinase (MMP) gene expression by protein kinases.
Front Biosci. 11:1199–1215. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim R, Emi M and Tanabe K: Cancer
immunoediting from immune surveillance to immune escape.
Immunology. 121:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang D, Fan X, Yin P, et al: Significance
of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2
(Erk1/2) in gastric cancer. BMC Immunol. 13:282012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chin YR and Toker A: Function of Akt/PKB
signaling to cell motility, invasion and the tumor stroma in
cancer. Cell Signal. 21:470–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun M, Wang G, Paciga JE, et al:
AKT1/PKBalpha kinase is frequently elevated in human cancers and
its constitutive activation is required for oncogenic
transformation in NIH3T3 cells. Am J Pathol. 159:431–437. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Staal SP: Molecular cloning of the akt
oncogene and its human homologues AKT1 and AKT2: amplification of
AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci
USA. 84:5034–5037. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Morrison CJ, Butler GS, Bigg HF, Roberts
CR, Soloway PD and Overall CM: Cellular activation of MMP-2
(gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway.
J Biol Chem. 276:47402–47410. 2001. View Article : Google Scholar : PubMed/NCBI
|
